ArticleThe Journal of clinical investigation2004
Development of antigen-specific ELISA for circulating autoantibodies to extracellular matrix protein 1 in lichen sclerosus.
Article in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- Alternations in the human skin, gut and vaginal microbiomes in perimenopausal or postmenopausal Vulvar lichen sclerosus.Scientific reports · 2024Article
- Article
- Characterization of patients with vulvar lichen sclerosus and association to vulvar carcinoma: a retrospective single center analysis.Archives of gynecology and obstetrics · 2023Article
- Lichen Sclerosus: A Current Landscape of Autoimmune and Genetic Interplay.Diagnostics (Basel, Switzerland) · 2022Review
- The Immunogenetics of Morphea and Lichen Sclerosus.Advances in experimental medicine and biology · 2022Review
- Alteration of gene expression related to vulvar smooth muscle, extracellular matrix and innervation in vulvar lichen sclerosus: A pilot study.Health science reports · 2020Article
- Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.Oncotarget · 2017Article
- Evaluation of Symptoms and Prevention of Cancer in Menopause: The Value of Vulvar Exam.Translational medicine @ UniSa · 2016Article
- Pediatric Lichen Sclerosus: A Review of the Literature and Management Recommendations.The Journal of clinical and aesthetic dermatology · 2016Review
- Extracellular matrix protein 1, a direct targeting molecule of parathyroid hormone-related peptide, negatively regulates chondrogenesis and endochondral ossification via associating with progranulin growth factor.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.Oncotarget · 2016Article
- Unusual remodeling of the hyalinization band in vulval lichen sclerosus by type V collagen and ECM 1 protein.Clinics (Sao Paulo, Brazil) · 2015Article
- The co-occurrence of lichen sclerosus et atrophicus and celiac disease.Indian dermatology online journal · 2014Article
- Phospholipid scramblase 1 is secreted by a lipid raft-dependent pathway and interacts with the extracellular matrix protein 1 in the dermal epidermal junction zone of human skin.The Journal of biological chemistry · 2010Article
- The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.Cellular and molecular life sciences : CMLS · 2010Review
- Interaction between cartilage oligomeric matrix protein and extracellular matrix protein 1 mediates endochondral bone growth.Matrix biology : journal of the International Society for Matrix Biology · 2010Article
- [Lichen sclerosus. New aspects of pathogenesis and treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen sclerosus is a common, acquired chronic inflammatory skin disease of unknown etiology, although circulating autoantibodies to the glycoprotein extracellular matrix protein 1 (ECM1) have been detected in most patients' sera. We have examined the nature of ECM1 epitopes in lichen sclerosus sera, developed an ELISA system for serologic diagnosis, and assessed clinicopathological correlation between ELISA titer and disease. Epitope-mapping studies revealed that lichen sclerosus sera most frequently recognized the distal second tandem repeat domain and carboxyl-terminus of ECM1. We analyzed serum autoantibody reactivity against this immunodominant epitope in 413 individuals (95 subjects with lichen sclerosus, 161 normal control subjects, and 157 subjects with other autoimmune basement membrane or sclerosing diseases). The ELISA assay was highly sensitive; 76 of 95 lichen sclerosus patients (80.0%) exhibited IgG reactivity. It was also highly specific (93.7%) in discriminating between lichen sclerosus and other disease/control sera. Higher anti-ECM1 titers also correlated with more longstanding and refractory disease and cases complicated by squamous cell carcinoma. Furthermore, passive transfer of affinity-purified patient IgG reproduced some histologic and immunopathologic features of lichen sclerosus skin. This new ELISA is valuable for the accurate detection and quantification of anti-ECM1 autoantibodies. Moreover, the values may have clinical significance in patients with lichen sclerosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.